Ambroxol Lipodisq Sterile Solution

Ambroxol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Ambroxol is a basic (pKa = 9.01) cationic drug with lipophilic properties (logP = 2.9), enabling it to act as a lysosomotropic agent. In addition, ambroxol exhibits a novel mechanism by accumulating in lamellar bodies and acting as a lysosomal secretagogue. A wide range of pharmacological effects of ambroxol has been confirmed, including mucus regulation, anti-inflammatory, reduction of arachidonic acid metabolites and pro-inflammatory cytokines, and antioxidant properties. In addition, ambroxol aids in the enhancement of local defense molecules involved in respiratory viral replication. Ambroxol is a sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes. Inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inhibits viral replication and improves the survival rate of mice infected with influenza (H3N2) virus. It is a candidate for use as an anti-COVID19 therapeutic. Ambroxol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.